Related Experiment Video
Updated: Aug 28, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
A Novel L-Phenylalanine Dipeptide Inhibits the Growth and Metastasis of Prostate Cancer Cells via Targeting DUSP1 and
Lanlan Li1,2,3, Mingfei Yang1, Jia Yu1,2
1State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China.
Abstract:
Prostate cancer (PCa) is a common malignant cancer of the urinary system. Drug therapy, chemotherapy, and radical prostatectomy are the primary treatment methods, but drug resistance and postoperative recurrence often occur. Therefore, seeking novel anti-tumor compounds with high efficiency and low toxicity from natural products can produce a new tumor treatment method. Matijin-Su [N-(N-benzoyl-L-phenylalanyl)-O-acetyl-L-phenylalanol, MTS] is a phenylalanine dipeptide monomer compound that is isolated from the Chinese ethnic medicine Matijin (Dichondra repens Forst.). Its derivatives exhibit various pharmacological activities, especially anti-tumor. Among them, the novel MTS derivative HXL131 has a significant inhibitory effect against prostate tumor growth and metastasis. This study is designed to investigate the effects of HXL131 on the growth and metastasis of human PCa cell lines PC3 and its molecular mechanism through in vitro experiments combined with proteomics, molecular docking, and gene silencing. The in vitro results showed that HXL131 concentration dependently inhibited PC3 cell proliferation, induced apoptosis, arrested cell cycle at the G2/M phase, and inhibited cell migration capacity. A proteomic analysis and a Western blot showed that HXL131 up-regulated the expression of proliferation, apoptosis, cell cycle, and migration-related proteins CYR61, TIMP1, SOD2, IL6, SERPINE2, DUSP1, TNFSF9, OSMR, TNFRSF10D, and TNFRSF12A. Molecular docking, a cellular thermal shift assay (CETSA), and gene silencing showed that HXL131 had a strong binding affinity with DUSP1 and TNFSF9, which are important target genes for inhibiting the growth and metastasis of PC3 cells. This study demonstrates that HXL131 exhibited excellent anti-prostate cancer activity and inhibited the growth and metastasis of prostate cancer cells by regulating the expression of DUSP1 and TNFSF9.
Insights
A novel compound, HXL131, derived from Matijin-Su, effectively inhibits prostate cancer (PCa) growth and metastasis. It targets key proteins DUSP1 and TNFSF9, offering a promising new avenue for PCa treatment.
Area of Science:
- Pharmacology and Natural Products Chemistry
- Oncology and Cancer Therapeutics
Background:
- Prostate cancer (PCa) treatment faces challenges like drug resistance and recurrence with current therapies.
- Natural products offer a source for novel anti-tumor compounds with potentially higher efficacy and lower toxicity.
- Matijin-Su (MTS) derivatives, including HXL131, show significant anti-cancer potential.
Purpose of the Study:
- To investigate the anti-prostate cancer effects of the MTS derivative HXL131 on human PCa cell lines (PC3).
- To elucidate the molecular mechanisms underlying HXL131's inhibition of PCa growth and metastasis.
- To identify potential molecular targets of HXL131.
Main Methods:
- In vitro experiments assessing cell proliferation, apoptosis, cell cycle, and migration.
- Proteomic analysis and Western blot to identify protein expression changes.
- Molecular docking, CETSA, and gene silencing to validate molecular targets.
Main Results:
- HXL131 dose-dependently inhibited PC3 cell proliferation, induced apoptosis, and arrested the cell cycle at G2/M phase.
- HXL131 significantly reduced PC3 cell migration capacity.
- HXL131 modulated the expression of key proteins involved in proliferation, apoptosis, cell cycle, and migration, notably up-regulating DUSP1 and TNFSF9.
Conclusions:
- HXL131 demonstrates potent anti-prostate cancer activity by inhibiting tumor cell growth and metastasis.
- The anti-cancer effects of HXL131 are mediated through the regulation of DUSP1 and TNFSF9 expression.
- HXL131 represents a promising therapeutic candidate for prostate cancer treatment.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

